Amgen (AMGN) Cash from Financing Activities (2009 - 2026)

Amgen (AMGN) has reported Cash from Financing Activities for 18 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 134.96% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at -$5.3 billion (up 55.0% YoY), while the FY2025 annual figure was -$10.9 billion, down 15.34% from the prior year.
• Cash from Financing Activities came in at $1.4 billion for Q1 2026 at Amgen, up from -$1.2 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $21.5 billion in Q1 2023, with the low at -$4.1 billion in Q1 2025.
• Average Cash from Financing Activities over 5 years is -$107.5 million, with a median of -$1.4 billion recorded in 2024.
• The largest YoY upside for Cash from Financing Activities was 712.09% in 2023 against a maximum downside of 226.26% in 2023.
• Year by year, Cash from Financing Activities stood at -$1.0 billion in 2022, then jumped by 362.54% to $2.8 billion in 2023, then plunged by 151.09% to -$1.4 billion in 2024, then gained by 12.86% to -$1.2 billion in 2025, then surged by 217.13% to $1.4 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.4 billion, -$1.2 billion, and -$2.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.